Noninvasive liver fibrosis assessment: Why does the APRI not work for hepatitis B?

We read the article by yilmaz et al. with interest (1).chronic liver disease requires the regular assessment of fibrosis to risk-stratify patients to treat and monitor the complications of liver cirrhosis (2). due to the overwhelming burden of liver disease worldwide, there is a patent need for noninvasive methods of assessing fibrosis to enable us to test large numbers of patients regularly. the aspartate transaminase-to-platelet ratio index (apri) is valuable, primarily due its universal availability, simplicity, and, hence, ease of use.